11/08/2025
A new drug application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for tavapadon, a once-daily treatment for Parkinson’s motor symptoms.
An NDA is one of the final steps in drug development, sharing clinical trial data on a treatment’s safety and effectiveness for FDA review.
Tavapadon is a dopamine agonist – a drug that mimics dopamine, the brain chemical that decreases in Parkinson’s. Unlike other dopamine agonists, tavapadon selectively stimulates only two of the five dopamine receptors in the brain. This more focused action may ease motor symptoms, potentially with fewer side effects that some other dopamine agonists can cause.
Learn more: https://bit.ly/4nM9Gfv